Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $39.1818.

Several analysts recently commented on the stock. Wedbush upped their price target on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a report on Monday, December 15th. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th.

Stoke Therapeutics Trading Down 1.3%

STOK stock opened at $31.99 on Tuesday. The company has a market capitalization of $1.83 billion, a P/E ratio of 47.75 and a beta of 1.10. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69. The business has a 50 day simple moving average of $31.50 and a 200-day simple moving average of $26.50.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 8,785 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65. Following the sale, the general counsel owned 15,809 shares of the company’s stock, valued at approximately $494,663.61. The trade was a 35.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Md Kaye sold 13,430 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the sale, the director directly owned 49,124 shares in the company, valued at $1,585,231.48. This trade represents a 21.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 98,774 shares of company stock worth $2,918,365. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harbour Investments Inc. lifted its stake in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics in the 3rd quarter valued at about $41,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the period. BNP Paribas Financial Markets grew its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.